Donald Gilbert, AAN 2022: Ecopipam investigated for the treatment of children and adolescents with Tourette’s syndrome – Phase 2b results

Ecopipam is an investigational first-in-class drug being evaluated for the treatment of children and adolescents with Tourette’s syndrome. Prof. Donald Gilbert (Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA) discusses the randomised, double-blind, placebo-controlled phase 2b study investigating ecopipam. 

The abstract entitled ‘Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.

Questions:

1. What is the rationale for using ecopipam for the treatment of children and adolescents with Tourette’s syndrome? (0:22)
2. Could you tell us a little about the Phase 2b study you are presenting and its findings? (1:31)
3. What was the safety and tolerability profile of ecopipam? (2:41)
4. What future studies are planned? (3:55)
5. What are your take home messages? (4:37)

Disclosures: Donald Gilbert is a consultant for Emalex, Eumentics Therapeutics, Applied Therapeutics; and has received grant/research Support from NINDS, NIMH and US DOD; and is on the Advisory Board for the Tourette Association; and has received honoraria/honorarium from Elsevier and Wolters Kluwer.

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022